SMAD4 and colorectal carcinoma: To further validate the relationship between SETD2 and the RAS/ERK signalling pathway in SMAD4‐deficient CRC, the ERK inhibitor SCH77298436 was administered to Smad4Vil‐KO;Setd2Vil‐KO mice as a therapeutic intervention.